Strategic Partners Opportunity to engage potential licensors or collaboration partners given Destiny Pharma’s lead asset XF-73 and NTCD-M3 with high clinical milestones and prior licensing challenges. Target pharmaceutical and biotech companies with complementary dermatology, infection prevention, or hospital-infection programs to explore licensing or co-development deals.

Clinical Assets XF-73 nasal gel and NTCD-M3 recurrence prevention program present near-term value propositions for infection prevention and microbiome-based therapies. Position as opportunities for distribution partners, contract sales, or regional licensing to accelerate market access in hospital settings and post-surgical care.

Financial Position Company currently under administration/liquidation with modest revenue and substantial funding history. Potential sales opportunities include asset divestiture, licensing exits, or structured investment deals with milestones, royalties, or upfront payments aligned to mid- to late-stage clinical milestones.

Market Fit Strong hospital-acquired infection and post-surgical infection prevention angles. Propose sales targets in hospital systems, infection control vendors, and sterilization service providers seeking novel preventive modalities or partnerships around CDI recurrence and MRSA-related risks.

Strategic Outreach Leverage recent executive and administrator changes to time outreach around licensing or asset consolidation opportunities. Coordinate with potential management or administration buyers, interim partners, or funders who specialize in turnaround opportunities within biotech portfolios.